FDA approves Alzheimer’s drug despite controversy over effectiveness

Published



The Food and Drug Administration has approved the Alzheimer’s drug aducanumab despite controversy over whether there is sufficient evidence to support the drug’s effectiveness.

Aducanumab is the first Alzheimer’s drug approved by the FDA in almost 20 years. It has been developed by the company Biogen in collaboration with a Japanese firm Eisai. It is the first drug approved that aims at a protein called amyloid beta that builds up in the brains of Alzheimer’s patients.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.